Sign Up
OverviewAPI
Arcutis Biotherapeutics, listed as ARQT on NASDAQ, has begun a $150 million equity raise through a public offering, leading to a 6.82% drop in share value. The company also offers underwriters a 30-day option to purchase additional $22.5 million worth of common stock.

Ask a question